Robert Rosenson, MD: RNAi Therapies Show Promise in Mixed Hyperlipidemia
Robert Rosenson, MD, discusses the unmet need in mixed hyperlipidemia and the potential for RNA interference therapies in this patient population.
Source: hcplive.com
Precision Biosciences News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Precision Biosciences. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Precision Biosciences Today - Breaking & Trending Today
DelveInsight Business Research, LLP: CAR T-Cell Therapy for Acute Lymphoblastic Leukemia Market to Register Stunning Growth by 2032, Predicts DelveInsight | Key Companies - AUTOLUS THERAPEUTICS, CELLECTIS, WUGEN, SERVIER, ALLOGENE, PRECISION BIOSCIENCES
The CAR T-cell therapy market for acute lymphoblastic leukemia is poised for substantial growth, driven by the anticipated launch of therapies such as OBECABTAGENE AUTOLEUCEL (OBE-CEL), UCART22
Source: finanznachrichten.de
Precision BioSciences (NASDAQ:DTIL) Earns "Buy" Rating from HC Wainwright
Precision BioSciences (NASDAQ:DTIL – Get Free Report)‘s stock had its “buy” rating reiterated by stock analysts at HC Wainwright in a report released on Thursday, Benzinga reports. They presently have a $60.00 price target on the stock. HC Wainwright’s price objective would indicate a potential upside of 399.17% from the company’s previous close. Separately, Guggenheim […]
Source: tickerreport.com
Precision BioSciences (NASDAQ:DTIL) Receives "Buy" Rating from HC Wainwright
Precision BioSciences (NASDAQ:DTIL – Get Free Report)‘s stock had its “buy” rating restated by HC Wainwright in a research report issued to clients and investors on Thursday, Benzinga reports. They currently have a $60.00 price target on the stock. HC Wainwright’s target price would indicate a potential upside of 399.17% from the stock’s current price. […]
Source: wkrb13.com